- Hyaluronan, which is given to boost viscoelasticity of synovial fluid and reduce pain in osteoarthritis (OA), comes in several different preparations.
- In this randomized controlled trial, a single intra-articular injection of chemically cross-linked hyaluronan (CCH) outperformed avian-derived hyaluronan (ADH) on almost all pain and disability measures.
Why this matters
- Clinicians should favor the use of CCH.
- Randomized, double-blind controlled trial (n=258) of CCH (60 mg/3 mL) vs ADH (60 mg/6 mL).
- Funding: None disclosed.
- The CCH group performed better on the following outcomes vs the ADH group (at 6 months compared with baseline):
- Reduced pain by visual analog scale (P<.0001>
- Lower total disability on the Western Ontario and McMaster Universities Osteoarthritis index (P<.0001>
- Improved Lequesne index for activities of daily living, walking distance, and pain (P<.0001 and>
- Better single-limb stance time for balancing on 1 knee (P<.0001>
- Single-center study.
- No placebo control.